Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR-T registry.
This registry documents when immunotherapy causes a serious inflammatory reaction, helping doctors recognize and manage a major safety concern in blood cancer CAR-T cell therapy.
DESCAR-T registry (LYSA/SFCE/GRAALL) characterises HLH-like syndrome incidence, clinical presentation, and outcomes post-CD19 CAR-T in B-cell lymphoma and B-ALL; major safety signal with management implications for CAR-T programmes. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- registry_study
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- HemaSphere
Why it surfaced
First large multicenter (LYSA/SFCE/GRAALL) registry study of HLH-like syndrome post-CAR-T; important safety signal with direct clinical management implications for hematologic malignancy programmes.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.